VIRTUS
← Back To Catalogue
Compound · Metabolic
Compound

Retatrutide

Retatrutide — GLP-1/GIP/Glucagon Triple Agonist

◇ Select Size
$45
10mgRETA-10MG
View COA
◇ About This Compound

A synthetic triple receptor agonist investigated in preclinical research for its activity at GLP-1, GIP, and glucagon receptors simultaneously. Retatrutide is among the most studied next-generation metabolic research compounds in current literature, with published data examining receptor binding kinetics, downstream signaling cascades, and energy homeostasis mechanisms at the cellular level.

LY3437943 is a triagonist peptide activating GLP-1, GIP, and glucagon receptors in concert. Preclinical data examines comparative receptor engagement versus dual agonists in adipose tissue models, hepatic lipid clearance pathways, and glucose-insulin axis signaling. Its extended half-life profile is conferred by a C20 fatty acid conjugate enabling extended dosing interval paradigms in research models.

◇ Specifications
Scientific Name
Retatrutide — GLP-1/GIP/Glucagon Triple Agonist
CAS Number
2381089-83-2
Molecular Formula
C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight
4,731.33 g/mol
Physical Form
Lyophilized powder
Purity
99%+
Batch Number
42565
Storage
−20°C, avoid repeated freeze-thaw cycles

◇ Research Use Only

This product is supplied as a high-purity research compound for in-vitro laboratory use only. Not for human or animal consumption. Not evaluated or approved by the FDA.

Independently tested for purity, weight, heavy metals, and endotoxins. Every batch ships with a Certificate of Analysis.